MedPath
HSA Approval

ACCOQUIN FILM COATED TABLET 200 MG

SIN16475P

ACCOQUIN FILM COATED TABLET 200 MG

ACCOQUIN FILM COATED TABLET 200 MG

April 13, 2022

ACCORD HEALTHCARE PRIVATE LIMITED

ACCORD HEALTHCARE PRIVATE LIMITED

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantACCORD HEALTHCARE PRIVATE LIMITED
Licence HolderACCORD HEALTHCARE PRIVATE LIMITED

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Prescription Only
HSA Singapore Classification

Formulation Information

TABLET, FILM COATED

**4.2 Posology and Method of Administration** Adults (including the elderly) The minimum effective dose should be employed. This dose should not exceed 6.5mg/kg/day (calculated from ideal body weight and not actual body weight) and will be either 200mg or 400mg per day. In patients able to receive 400mg daily: Initially 400mg daily in divided doses. The dose can be reduced to 200mg when no further improvement is evident. The maintenance dose should be increased to 400mg daily if the response lessens. Children: The minimum effective doses should be employed and should not exceed 6.5mg/kg/day based on ideal body weight. The 200mg tablet is therefore not suitable for use in children with an ideal body weight of less than 31 kg. Each dose should be taken with a meal or glass of milk. Hydroxychloroquine is cumulative in action and will require several weeks to exert its beneficial effects, whereas minor side effects may occur relatively early. For rheumatic disease treatment should be discontinued if there is no improvement by 6 months. In light-sensitive diseases, treatment should only be given during periods of maximum exposure to light. The tablets are for oral administration.

ORAL

Medical Information

**4.1 Therapeutic Indications** Treatment of rheumatoid arthritis, juvenile chronic arthritis, discoid and systemic lupus erythematosus, and dermatological conditions caused or aggravated by sunlight.

**4.3 Contraindications** - known hypersensitivity to 4-aminoquinoline compounds - pre-existing maculopathy of the eye - Below 6 years of age (200 mg tablets not adapted for weight <35 kg) or for ideal body weight < 31 kg

P01BA02

hydroxychloroquine

Manufacturer Information

ACCORD HEALTHCARE PRIVATE LIMITED

Intas Pharmaceuticals Limited

Active Ingredients

Hydroxychloroquine Sulfate

200.0 mg

Hydroxychloroquine

Documents

Package Inserts

Accoquin Film Coated Tablet 200mg package insert.pdf

Approved: April 13, 2022

Download

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

ACCOQUIN FILM COATED TABLET 200 MG - HSA Approval | MedPath